The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

CAR-T Therapies Market, 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    July 2018

  • Pages
    548

  • View Count
    3049

Example Insights

An updated edition is available at the following link 

View 2nd edition

 

Overview

In my opinion, when it comes to CAR-T cells, every detail matters, including the CAR construct, type of disease targeted, type of cytokine used to culture the cells, condition of the patients, and their pre-treatment history, taking into consideration the patient’s heart and kidney function. As the therapy is new, people have not yet understood how to handle the side-effects; however, I believe that eventually we will learn to take care of these toxicities as we treat more patients

-Principle Investigator, US based academic research institute

Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. There are certain key characteristics that render CAR-T cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 70 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Given the recent approval of two CAR-T therapies, namely Kymriah® (Novartis) and Yescarta® (Gilead Sciences), and a robust development pipeline, the CAR-T therapy market also offers considerable promise to a number of industry stakeholders.

 

Scope of the Report

The “CAR-T Therapies Market, 2018-2030” report features an extensive study of the current market landscape and the future potential of CAR-T therapies. One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms. Amongst other elements, the report features the following:

  • An analysis depicting prevalent and emerging trends related to CAR-T therapies as observed on the social media platform, Twitter. In addition to the yearly chatter trends, the analysis highlights the most frequently talked about product candidates as well.
  • A detailed assessment of the current market landscape of CAR-T therapies with respect to type of developer (industry and non-industry), phase of development, target therapeutic indications, key target antigens, source of T-cells (autologous and allogenic), and route of administration (intravenous infusion and regional route).
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process of the therapy (wherever available).
  • An analysis of the CAR constructs of clinical stage therapies based on generation of CAR-T product (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA electroporation, sleeping beauty and other vectors) and type of co-stimulatory domain used.
  • An analysis of the CAR-T clinical trials registered across the world in the period between 2009 and 2018, highlighting the year wise trend and the geographical distribution.
  • A detailed analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of CAR-T therapies.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of CAR-T therapies, along with profiles of key technology providers.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies, featuring different models / approaches that a pharmaceutical company may choose to adopt to decide the price of its proprietary products that are likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-T therapies, Kymriah® and Yescarta®.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The report includes information on (potential) sales-based revenues of CAR-T therapies that are currently marketed or are in late stages of development. Additionally, it presents detailed segmentation of the overall opportunity on the basis of geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, hepatocellular carcinoma and non-Hodgkin’s lymphoma). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital).

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T therapy market in the short to mid-term and long term.

Chapter 3  provides a general overview of CAR-T therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the conception and historical evolution of cancer immunotherapy, general manufacturing procedures used for the production of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapeutic options.

Chapter 4  focuses on CAR-T therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It features details on the historical development of CAR-T products, such as the structure of CAR-T constructs (including information on all four generations of CAR-Ts), a discussion on the process of CAR-T development, molecular targets that are currently under investigation (for the development of such therapeutic products) and the current challenges (such as toxicity issues) that are associated with this therapy segment.

Chapter 5  provides insights on the popularity of CAR-T therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2017, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords and drug candidates, as observed on social media.

Chapter 6  provides information on around 366 CAR-T cell therapies that are currently in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of developer(s), phase of development, target therapeutic areas and disease indications, key target antigens, source of T-cells (autologous and allogenic) and route of administration (intravenous infusion and regional route). Further, the chapter identifies the most active players ( in terms of number of pipeline candidates ) and features a logo landscape representation, highlighting product developers in North America, Europe and the Asia Pacific region. In addition, it includes an analysis of the CAR constructs that are presently being used in clinical stage CAR-T therapies on the basis of generation of CAR product, type of binding domain, type of vector and type of co-stimulatory domain.

Chapter 7  presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T therapies being developed against hematological cancers and solid tumors. Further, the chapter includes an analysis of global CAR-T trials that were registered in the time period between 2009 to 2018, featuring the year wise trend and distribution of CAR-T trials across different geographies. In addition, it includes a comprehensive analysis of close to 290 clinical trials (completed / ongoing) to evaluate CAR-T therapies with respect to the phase of development, patient segment (children, adults and senior citizens), and type of therapy (monotherapy and combination therapy). To offer due credit to the work of eminent researchers in this domain, we have also mapped the presence of key opinion leaders (who are involved in this field of research) across the globe.

Chapter 8  includes detailed profiles of approved / late stage CAR-T therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, manufacturing process, estimated cost of treatment and treatment regimen details.

Chapter 9  highlights the most common therapeutic indications targeted by CAR-T therapies, and features brief discussions on the CAR-T therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 10  provides a list of technology platforms that are either available in the market or under development, for designing and / or manufacturing CAR-T therapies. It features brief profiles of some of the key technologies; each profile contains details on the various pipeline molecules that have been / are being developed using the technology, its advantages and the associated partnerships.

Chapter 11  provides insights on the cell therapy manufacturing process, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining such manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house capabilities. For all the players mentioned in this chapter, we have included details on location of manufacturing facilities, products manufactured, scale of operation and compliance to cGMP standards.

Chapter 12  highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement considerations for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapies.

Chapter 13  features an elaborate discussion on the commercial opportunity associated with CAR-T therapies. It provides a comprehensive market forecast analysis for therapies that are either already approved or are in the mid-phases of clinical development (phase I/II, phase II and phase III), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed segmentation of the opportunity on the basis of geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, hepatocellular carcinoma and non-Hodgkin’s lymphoma).

Chapter 14  highlights the key promotional strategies that are being implemented by the developers of the marketed products, Kymriah® and Yescarta®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 15  includes brief company profiles of the leading players in the CAR-T therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T therapies, affiliated technology portfolio ( if available ), recent developments related to CAR-T therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 16  is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17  is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Enkhtsetseg Purev (Assistant Professor Of Medicine, University Of Colorado), Miguel Forte (Chief Operating Officer, TxCell), Vincent Brichard (Vice President, Immuno-Oncology, Celyad) and Xian-Bao Zhan (Professor Of Medicine and Director, Department Of Oncology, Changhai Hospital).

Chapter 18  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19  is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Immunotherapy, an Emerging Therapeutic Option
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell Based Therapies
 
3.6. Evolution of T-Cell Immunotherapies
3.7. Key Considerations for T-Cell Immunotherapies
3.8. Strategies Employed for Redirection of T-Cells
3.9. Manufacturing of Engineered T-Cells
3.10. T-Cell Transduction / Transfection Methods
3.10.1. Retroviral Vectors
3.10.2. Lentiviral Vectors
3.10.3. Non-viral Transfection Methods
3.10.3.1. Sleeping Beauty Transposon
 
3.11. T-Cell Immunotherapy: Targeted Therapeutic Areas
3.12. T-Cell Immunotherapies: Key Challenges
 
4. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
4.1. Chapter Overview
4.2. History of Development
4.3. Anatomical Layout of Chimeric Antigen Receptor
4.4. Development Of CAR-T Therapies
4.5. Universal CAR-Ts
4.6. Preferred Routes of Administration
 
4.7. Toxicity Issues
4.7.1. Cytokine Release Syndrome (CRS)
4.7.2. On-Target, Off-Tumor Toxicity
4.7.3. Encephalopathy and B-Cell Aplasia
4.7.4. Neurological Toxicity
4.7.5. Anaphylaxis
4.7.6. Insertional Oncogenesis
4.7.7. Graft versus Host Disease (GVHD)
 
4.8. Management of Toxicity Issues
4.8.1. Pharmacological Immunosuppression
4.8.2. Target Selection
4.8.3. Safety Switches
4.8.4. Elimination Genes
4.8.5. Receptor Expression
 
4.9. CD19: An Attractive Target
4.10. Other Targets
4.11. Challenges Associated with CAR-T Therapy
4.11.1. Competitive Risks
4.11.2. Clinical Risks
4.11.3. Regulatory Risks
4.11.4. Commercial Risks
 
5. EMERGING TRENDS ON SOCIAL MEDIA
5.1. Chapter Overview
5.2. Trends on Twitter
5.2.1. Social Media Analysis: Yearly Trends on Twitter
5.2.2. Social Media Analysis: Popular Keywords on Twitter
5.3. Social Media Analysis: Most Popular Drugs on Twitter
 
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Therapies: Pipeline Overview
6.2.1. Distribution by Type of Developer
6.2.2. Distribution by Phase of Development
6.2.3. Target Oncological Indications
6.2.3.1. Popular Target Indications
6.2.4. Popular Target Antigens
6.2.5. Distribution by Source of T-Cells
6.2.6. Distribution by Route of Administration
6.2.7. Key Industry Players
6.2.8. Key Non-Industry Players
 
6.3. CAR-T Therapies: Analysis of CAR Constructs
6.3.1. Analysis by Generation of CAR-T Therapies
6.3.2. Analysis by Type of scFv Antibody
6.3.3. Analysis by Type of Vector
6.3.4. Analysis by Type of Co-Stimulatory Domain(s)
 
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Therapies: Analysis by Popularity of Target Antigens
7.2.1. Hematological Cancers: Popular Targets
7.2.1.1. CD19 CAR-T Therapies: Competitive Landscape
7.2.1.2. CD19 CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates
7.2.1.3. BCMA CAR-T Therapies: Competitive Landscape
7.2.1.4. BCMA CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates
7.2.2. Solid Tumors: Popular Targets
7.2.2.1. Meso CAR-T Therapies: Competitive Landscape
7.2.2.2. GD2 CAR-T Therapies: Competitive Landscape
 
7.3. CAR-T Therapies: Clinical Trial Trends, 2009-2018
7.3.1. Analysis by Trial Registration Year
7.3.2. Geographical Analysis by Number of Registered Trials
 
7.4. CAR-T Therapies: Clinical Trial Overview
7.4.1. Clinical Trial Analysis: Distribution by Phase of Development
7.4.2. Clinical Trial Analysis: Distribution by Patient Segment
7.4.3. Clinical Trial Analysis: Distribution by Type of Therapy
 
7.5. CAR-T Therapies: Key Opinion Leaders
7.5.1. Most Prominent Key Opinion Leaders
 
8. MARKETED AND LATE-STAGE CAR-T THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. History of Development
8.2.3. Current Development Status
8.2.4. Key Clinical Trial Results
8.2.5. Dosage Regimen, Price and Manufacturing
 
8.3. Yescarta® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.3.5. Next Generation eACT CAR Candidates
8.4. JCAR (Juno Therapeutics)
8.4.1. Therapy Overview
8.4.2. CAR-T Design
8.4.3. Development Status
8.4.4. Key Clinical Results
8.4.4.1. JCAR014
8.4.4.2. JCAR017
8.4.4.3. JCAR018
8.4.5. Dosage Regimen and Manufacturing
 
8.5. CAR-T Series (Cellular Biomedicine Group)
8.5.1. Therapy Overview
8.5.2. History of Development
8.5.3. Current Development Status
8.5.4. Key Clinical Trial Results
8.5.4.1. CBM-EGFR.1
8.5.4.2. CBM-C19.1
8.5.4.1. CBM-C20.1
8.5.4.2. CBM-C30.1
8.5.5. Dosage Regimen and Manufacturing
8.5.6. Patent Portfolio
 
8.6. CD19 CAR (Takara Bio)
8.6.1. Therapy Overview
8.6.2. Current Developmental Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
 
8.7. Dual Targeting CAR-T Cell therapies (Autolus)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
 
8.8. CAR-T Therapies (Sinobioway Cell Therapy)
8.8.1. Therapy Overview
8.8.2. Current Development Status
 
9. KEY THERAPEUTIC AREAS CAR-T THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
 
9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies
9.2.1.4. CAR-T Therapy and Research Landscape
 
9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. CAR-T Therapy and Research Landscape
 
9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. CAR-T Therapy and Research Landscape
 
9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. CAR-T Therapy and Research Landscape
 
9.3.3. Bladder Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. CAR-T Therapy and Research Landscape
 
9.3.4. Kidney Cancer
9.3.4.1. Introduction and Epidemiology
9.3.4.2. Current Treatment Landscape
9.3.4.3. CAR-T Therapy and Research Landscape
 
9.3.5. Ovarian Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. CAR-T Therapy and Research Landscape
 
9.3.6. Breast Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. CAR-T Therapy and Research Landscape
 
10. EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Genome Editing Technologies
10.2.1. Technology Overview
10.2.2. Applications
10.2.3. Emerging Technology Platforms Used in CAR-T Therapies
10.2.3.1. CRISPR/Cas9 System
10.2.3.1.1. Key Components and Function
10.2.3.1.2. Mechanism of Action
10.2.3.1.3. Targeting Efficiency and Challenges
10.2.3.1.4. Next-GEN CRISPR Technology
10.2.3.1.5. Technology Providers
 
10.2.3.2. TALENs
10.2.3.2.1. Key Components and Function
10.2.3.2.2. Mechanism of Action
10.2.3.2.3. Advantages and Challenges
10.2.3.2.4. Technology Providers
 
10.2.3.3. megaTAL
10.2.3.3.1. Technology Providers
 
10.2.3.4. Zinc Finger Nuclease
10.2.3.4.1. Technology Providers
 
10.3. Designing T-Cell Therapies with Improved Characteristics
10.3.1. Technologies for Targeting Multiple Cancers
10.3.1.1. NKR-T Platform (Celyad)
 
10.3.2. Technologies for Improved Safety
10.3.2.1. Armored CAR and EGFRt technology (Juno Therapeutics)
10.3.2.2. RheoSwitch Therapeutic System (Intrexon)
10.3.2.3. Inducible Caspase 9 Safety Switch (Bellicum Pharmaceuticals)
10.3.2.3.1. CaspaCIDe Technology
10.3.2.3.2. CIDeCAR Technology
10.3.2.3.3. GoCAR-T Technology
 
10.3.2.4. On-Off Switch, Multiple Companies
10.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
10.3.2.4.2. On-Off Switch (Theravectys)
10.3.2.5. Other Technologies to Improve CAR-T Safety
 
10.3.3. Allogeneic Technologies
10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
10.3.3.2. Allogeneic Platform (Celyad)
10.3.3.3. Allogeneic Platform (Cellectis)
 
11. CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. Introduction
11.3. Key Challenges
11.4. Current Trends
11.4.1. Companies with In-House Capabilities
11.4.2. Contract Manufacturers
11.5. Key Considerations for a Manufacturing Site
11.6. Regulatory Landscape
 
12. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the Price of Cell / Gene Therapies
 
12.3. Pricing Models for T-Cell Immunotherapies
12.3.1. On the Basis of Associated Costs
12.3.2. On the Basis of Competition
12.3.3. On the Basis of Patient Segment
12.3.4. On the Basis of Expert Opinions
 
12.4. Reimbursement Considerations for T-Cell Immunotherapies
12.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapy
 
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology
 
13.4. Overall CAR-T Therapy Market
13.4.1. CAR-T Therapy Market: Distribution by Geography
13.4.2. CAR-T Therapy Market: Distribution by Target Indications
 
13.5. CAR-T Therapy Market: Product-Wise Sales Forecasts
13.5.1. Kymriah® (Novartis)
13.5.1.1. Target Population
13.5.1.2. Sales Forecast
 
13.5.2. Yescarta® (Gilead Sciences)
13.5.2.1. Target Population
13.5.2.2. Sales Forecast
 
13.5.3. bb2121 (Celgene / bluebird bio)
13.5.3.1. Target Population
13.5.3.2. Sales Forecast
 
13.5.4. MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center)
13.5.4.1. Target Population
13.5.4.2. Sales Forecast
 
13.5.5. CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
13.5.5.1. Target Population
13.5.5.2. Sales Forecast
 
13.5.6. GPC3 CAR-T (Shanghai GeneChem)
13.5.6.1. Target Population
13.5.6.2. Sales Forecast
 
13.5.7. TBI-1501 (Takara Bio / Jichi Medical University)
13.5.7.1. Target Population
13.5.7.2. Sales Forecast
 
13.5.8. JCAR017 (Juno Therapeutics / Celgene)
13.5.8.1. Target Population
13.5.8.2. Sales Forecast
 
13.5.9. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
13.5.9.1. Target Population
13.5.9.2. Sales Forecast
 
13.5.10. PCAR-019 (PersonGen BioTherapeutics)
13.5.10.1. Target Population
13.5.10.2. Sales Forecast
 
13.5.11. AUTO2 (Autolus)
13.5.11.1. Target Population
13.5.11.2. Sales Forecast
 
13.5.12. AUTO3 (Autolus)
13.5.12.1. Target Population
13.5.12.2. Sales Forecast
 
13.5.13. BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital)
13.5.13.1. Target Population
13.5.13.2. Sales Forecast
 
13.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology / Henan Cancer Hospital)
13.5.14.1. Target Population
13.5.14.2. Sales Forecast
 
13.5.15. CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University)
13.5.15.1. Target Population
13.5.15.2. Sales Forecast
 
13.5.16. LCAR-B38M CAR-T (Nanjing Legend Biotech)
13.5.16.1. Target Population
13.5.16.2. Sales Forecast
 
13.5.17. CD19 CAR-T (Shanghai Bioray Laboratory)
13.5.17.1. Target Population
13.5.17.2. Sales Forecast
 
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Support Services and Informative Downloads
 
14.5. Kymriah®: Promotional Analysis
14.5.1. Drug Overview
14.5.2. Product Website Analysis
14.5.2.1. Messages for Healthcare Professionals
14.5.2.2. Messages for Patients
14.5.3. Patient Support Services and Informative Downloads
14.5.4. Other Promotional Activities
14.5.4.1. Presence in Conferences
 
14.6. Yescarta®: Promotional Analysis
14.6.1. Drug Overview
14.6.2. Product Website Analysis
14.6.2.1. Messages for Healthcare Professionals
14.6.2.2. Messages for Patients
14.6.3. Patient Support Services and Informative Downloads
14.6.4. Other Promotional Activities
14.6.4.1. Presence in Conferences
 
15. COMPANY PROFILES
15.1. Chapter Overview
15.2. Autolus
15.3. bluebird bio
15.4. CARsgen Therapeutics
15.5. Celgene
15.6. Cell Medica
15.7. Cellectis
15.8. Cellular Biomedicine Group
15.9. Innovative Cellular Therapeutics
15.10. Kite Pharma (A Gilead Sciences Company)
15.11. Novartis
15.12. Sinobioway Cell Therapy
15.13. Takara Bio
15.14. ZIOPHARM Oncology
 
16. CONCLUSION
16.1. CAR-T Therapies Market is Characterized by a Robust Pipeline of Over 350 Product Candidates Being Developed for Various Oncological Indications
16.2. The Primary Focus of CAR-Based Therapeutic Interventions is on Hematological Malignancies and Solid Tumors
16.3. Both Established Players and Start-Ups are Actively Involved in Developing CAR-T Therapies; Academic Institutes Continue to Make Significant Contributions to the Innovation in this Domain
16.4. Several Innovative Technology Platforms have been Developed, and are Expected to Enable the Development of Better Therapies, With Favorable Safety and Efficacy Profiles
16.5. Owing to High R&D Investments, CAR-T Therapies Bear Premium Price Tags; Developers are Striving to Offer Reimbursement Plans and Implement Various Promotional Strategies to Achieve Commercial Success
16.6. Post the Approval of Multiple Late-Phase Product Candidates, the Market is Anticipated to Grow at a Rapid Pace in the Foreseen Future
 
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Enkhtsetseg Purev, Assistant Professor of Medicine, University of Colorado (Q1 2018)
17.3. Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology, Changhai Hospital (Q4 2017)
17.4. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing (Q1 2017)
17.5. Miguel Forte, Chief Operating Officer, TxCell (Q3 2016)
17.6. Adrian Bot, Vice President, Scientific Affairs, Kite Pharma (Q1, 2016)
17.7. Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys (Q3, 2015)
17.8. Vincent Brichard, Vice President, Immuno-Oncology, Celyad (Q3 2015)
 
18. APPENDIX 1: TABULATED DATA
 
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  The Four Pillars of Cancer Therapy
Figure 3.2  Differences between Active and Passive Immunotherapies
Figure 3.3  Differences between Specific and Non-Specific Immunotherapies
Figure 3.4  3Es of the Immune System
Figure 3.5  Strategies Employed for the Redirection of T-Cells
Figure 3.6  T-Cell Manufacturing: General Procedure
Figure 3.7  T-Cell Immunotherapies: Targeted Therapeutic Areas
Figure 3.8  T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1  Historical Timeline: Development of CAR-T cells
Figure 4.2  CAR-T: Structure and Domains
Figure 4.3  CAR Generations: Structural Layout 
Figure 4.4  Development of CAR-T Therapies
Figure 4.5  Challenges Associated with CAR-T Therapy
Figure 5.1 Social Media Analysis: Twitter Trends, January 2012-November 2017
Figure 5.2  Social Media Analysis: Popular Keywords on Twitter, January 2012-November 2017
Figure 5.3  Social Media Analysis: Twitter, Most Popular Candidates, January 2012-November 2017
Figure 6.1  CAR-T Therapy Pipeline: Distribution by Type of Developer
Figure 6.2  CAR-T Therapy Pipeline: Distribution by Phase of Development
Figure 6.3  CAR-T Therapy Pipeline: Distribution by Target Therapeutic Area
Figure 6.4  CAR-T Therapy Pipeline: Popular Target Indications
Figure 6.5  CAR-T Therapy Pipeline: Distribution by Target Antigen
Figure 6.6  CAR-T Therapy Pipeline: Distribution by Source of T-Cells
Figure 6.7  CAR-T Therapy Developer Landscape: Distribution by Source of T-Cells 
Figure 6.8  CAR-T Therapy Pipeline: Distribution by Route of Administration
Figure 6.9  CAR-T Therapy Pipeline: Active Industry Players in Clinical Development
Figure 6.10  CAR-T Therapy Pipeline: Active Industry Players in Preclinical Development
Figure 6.11  CAR-T Therapy Pipeline: Active Non-Industry Players in Clinical Development
Figure 6.12  CAR-T Therapy Pipeline: Active Non-Industry Players in Preclinical Development
Figure 6.13  CAR-Construction: Distribution by Generation of CAR-T Therapies
Figure 6.14  CAR-Construction: Distribution by Type of scFv Used in CAR-T Therapies
Figure 6.15  CAR-Construction: Distribution by Type of Vector
Figure 6.16  CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 7.1  CAR-T Therapies: Popular Targets in Hematological Cancer
Figure 7.2  CAR-T Therapies: Popular Targets in Solid Tumor
Figure 7.3  CAR-T Clinical Trials: Cumulative Trend (2009-2018)
Figure 7.4  CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
Figure 7.5  CAR-T Therapies: Distribution of Clinical Trials by Phase of Development
Figure 7.6  CAR-T Therapies: Distribution of Clinical Trials by Patient Segment
Figure 7.7  CAR-T Therapies: Distribution of Clinical Trials by Type of Therapy
Figure 7.8  CAR-T Therapies: Geographical Distribution of Key Opinion Leaders
Figure 7.9  CAR-T Therapies: Prominent Key Opinion Leaders
Figure 8.1  Kymriah®: Industry Sponsored Clinical Trial Design
Figure 8.2  Kymriah®: Non-Industry Sponsored Clinical Trial Design
Figure 8.3  Yescarta®: Clinical Trial Design
Figure 8.4  Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 8.5  JCAR Series: Industry Sponsored Clinical Trial Design
Figure 8.6  JCAR Series: Non-Industry Sponsored Clinical Trial Design
Figure 8.7  Cellular Biomedicine’s CAR-T Series: Clinical Trial Design
Figure 8.8  Takara Bio’s CD19 CAR-T: Clinical Trial Design
Figure 8.9  Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 8.10  Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 9.1 Leukemia: Classification
Figure 9.2  Leukemia: Global Epidemiological Distribution
Figure 9.3  Lymphoma: Global Epidemiological Distribution
Figure 9.4  Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5  Melanoma: Global Epidemiological Distribution
Figure 9.6  Lung Cancers: Classification
Figure 9.7  Lung Cancer: Global Epidemiological Distribution
Figure 9.8  Bladder Cancer: Global Epidemiological Distribution
Figure 9.9  Kidney Cancer: Global Epidemiological Distribution
Figure 9.10  Ovarian Cancer: Global Epidemiological Distribution
Figure 9.11 Breast Cancer: Global Epidemiological Distribution
Figure 10.1 Genome Editing Technologies: Applications
Figure 10.2  Genome Editing: Emerging Technology Platforms Used in CAR-T Therapies
Figure 10.3  Key Technologies to Enhance Features / Characteristics of CAR-T Therapies
Figure 10.4  Cellectis: Properties of Enhanced T-Cell Platform
Figure 10.5  Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1  Cell Therapy Manufacturing: Key Steps
Figure 11.2  Cell Therapy Manufacturing: Scenarios
Figure 11.3  T-Cell Immunotherapy Manufacturing: Key Collaborations
Figure 12.1  Targeted Therapies: Pricing Model Based on Patient Segment
Figure 13.1  Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
Figure 13.2  CAR-T Therapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 13.3  CAR-T Therapy Market: Distribution by Target Indication, 2018, 2025 and 2030 (USD Billion)
Figure 13.4  Kymriah® (Novartis): Current Status of Development
Figure 13.5  Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.6  Yescarta® (Gilead Sciences): Current Status of Development
Figure 13.7  Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.8  bb2121 (Celgene / bluebird bio): Current Status of Development
Figure 13.9  bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.10  MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center): Current Status of Development
Figure 13.11  MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.12  CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University): Current Status of Development
Figure 13.13  CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.14  GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 13.15  GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.16  TBI-1501 (Takara Bio / Jichi Medical University): Current Status of Development
Figure 13.17  TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.18  JCAR017 (Juno Therapeutics / Celgene): Current Status of Development
Figure 13.19  JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.20  IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 13.21  IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.22 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 13.23  PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.24  AUTO2 (Autolus): Current Status of Development
Figure 13.25  AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.26 AUTO3 (Autolus): Current Status of Development
Figure 13.27  AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.28  BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital): Current Status of Development
Figure 13.29  BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.30  CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital): Current Status of Development
Figure 13.31  CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.32  CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University): Current Status of Development
Figure 13.33  CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.34  LCAR-B38M CAR-T (Nanjing Legend Biotech): Current of Development
Figure 13.35  LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.36  CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 13.37  CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 14.1  Promotional / Marketing Strategy: Product Website Analysis
Figure 14.2  Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 14.3  Product Website Analysis: Kymriah®, Messages for Healthcare Professionals
Figure 14.4  Product Website Analysis: Kymriah®, Messages for Patients
Figure 14.5  Product Website Analysis: Kymriah®, Patient Support Program
Figure 14.6  Kymriah®, Presence in Conferences
Figure 14.7  Product Website Analysis: Yescarta®, Messages for Healthcare Professionals
Figure 14.8  Product Website Analysis: Yescarta®, Messages for Patients
Figure 14.9  Product Website Analysis: Yescarta®, Kite Konnect
Figure 14.10  Product Website Analysis: Yescarta®, Platform for Products Complaints, Reporting Adverse Events and Requesting Medical Information
Figure 14.11  Yescarta®, Presence in Conferences
Figure 16.1  CAR-T Therapy Market Landscape: Non-Industry Participants
Figure 16.2  CAR-T Therapy Market Landscape: Industry Participants
Figure 16.3  CAR-T Therapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

 

List of Tables

Table 3.1  Types of Immunotherapies and Affiliated Mechanisms of Action
Table 4.1  Key Characteristics of CAR-T Cells
Table 4.2  Comparison Between First and Second-Generation CARs
Table 4.3  Grading Criteria for CRS
Table 4.4  Safety Switches under Development for CAR-T Therapy
Table 4.5  CD19 CAR-T Cells: Preclinical Results
Table 4.6  Other Targets under Clinical / Preclinical Studies for CAR-T Therapy
Table 6.1  CAR-T Therapies: Clinical Pipeline 
Table 6.2  CAR-T Therapies: Preclinical Pipeline
Table 6.3  CAR-T Therapies: Information on Constructs of Clinical Candidates, 
Table 7.1  CD19 CAR-T Therapies: Competitive Landscape
Table 7.2  CD19 CAR-T Therapies: Clinical Outcomes
Table 7.3  BCMA CAR-T Therapies: Competitive Landscape
Table 7.4  BCMA CAR-T Therapies: Clinical Outcomes
Table 7.5  Meso CAR-T Therapies: Competitive Landscape
Table 7.6  GD2 CAR-T Therapies: Competitive Landscape
Table 7.7  CAR-T Therapies: Clinical Trials 
Table 7.8  CAR-T Therapies: Principle Investigators
Table 8.1  Kymriah®: Current Status of Development
Table 8.2  Kymriah®: Clinical Trial Endpoints (ALL)
Table 8.3 Kymriah®: Clinical Trial Endpoints (CLL/MM/NHL)
Table 8.4  Yescarta®: Current Status of Development
Table 8.5  Yescarta®: Clinical Trial Endpoints
Table 8.6  Yescarta®: ZUMA-1 Phase II (6 months Follow-Up)
Table 8.7  Yescarta®: ZUMA-1 Phase II Results (≥3 months Follow-Up)
Table 8.8  Yescarta®: ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
Table 8.9  JCAR Series: Molecules in Clinical Development
Table 8.10  JCAR: CAR-T Design
Table 8.11  JCAR014: Current Status of Development
Table 8.12  JCAR017: Current Status of Development
Table 8.13  JCAR018: Current Status of Development
Table 8.14  JCAR020: Current Status of Development
Table 8.15  JCAR023: Current Status of Development
Table 8.16  JCAR024: Current Status of Development
Table 8.17  JCAR Series: Clinical Trial Endpoints (Phase II)
Table 8.18 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.19  JCAR: Dosage Regimen
Table 8.20  CBM CAR-T Series: Clinical Products, 
Table 8.21  CBM-CD19.1 CAR-T: Current Status of Development
Table 8.22  CBM-CD20 CAR-T: Current Status of Development
Table 8.23  CBM-CD30.1 CAR-T: Current Status of Development
Table 8.24  CBM-EGFR.1 CAR-T: Current Status of Development
Table 8.25  CBM CAR-T Series: Clinical Trial Endpoints
Table 8.26  CBM CAR-T Series: Patent Portfolio
Table 8.27  Takara Bio’s CD19 CAR-T: Current Status of Development
Table 8.28  Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 8.29  TBI-1501: Dosage Regimen
Table 8.30  AUTO2: Current Status of Development
Table 8.31  AUTO3: Current Status of Development
Table 8.32  Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.33  Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Current Status of Development
Table 8.34  Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Current Status of Development
Table 8.35  Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.36  Phase I/II or Phase II CAR-T Therapies from the Industry Players
Table 9.1  Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Leukemia: List of Marketed Targeted Therapeutics
Table 9.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 9.4  CAR-T Therapies: Targets under Investigation for Leukemia
Table 9.5  CAR-T Therapies: Targets under Investigation for Lymphoma
Table 9.6  Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 9.7  CAR-T Therapies: Targets under Investigation for Multiple Myeloma
Table 9.8  Melanoma: List of Marketed Targeted Therapeutics
Table 9.9  Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.10  CAR-T Therapies: Targets under Investigation for Lung Cancer
Table 9.11  Bladder Cancer: List of Marketed Targeted Therapeutics
Table 9.12  Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 9.13  Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.14  CAR-T Therapies: Targets under Investigation for Ovarian Cancer
Table 9.15  Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.16  CAR-T Therapies: Targets under Investigation for Breast Cancer
Table 10.1  Editas Medicine: CRISPR/Cas9 Technology, Research Publications
Table 10.2  Editas Medicine: Funding Instances
Table 10.3  Editas Medicine: Collaborations
Table 10.4  Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
Table 10.5  Intellia Therapeutics: Funding Instances
Table 10.6  Intellia Therapeutics: Collaborations
Table 10.7  CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
Table 10.8  CRISPR Therapeutics: Funding Instances
Table 10.9  CRISPR Therapeutics: Collaborations
Table 10.10  Cellectis: Funding Instances
Table 10.11  Cellectis: Collaborations
Table 10.12  bluebird bio: megaTAL Technology, Research Publications
Table 10.13  bluebird bio: Funding Instances
Table 10.14  bluebird bio: Collaborations
Table 10.15  Sangamo Therapeutics: Funding Instances
Table 10.16  Sangamo Therapeutics: Collaborations
Table 10.17  Celyad: Funding Instances
Table 10.18  Celyad: Collaborations
Table 10.19  Intrexon: Funding Instances
Table 10.20  Intrexon: Collaborations
Table 10.21  Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.22  Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.23  Bellicum Pharmaceuticals: Funding Instances
Table 10.24  Bellicum Pharmaceuticals: Collaborations
Table 10.25  Theravectys: Funding Instances
Table 10.26  Technologies For CAR-T Safety Enhancement
Table 10.27  Formula Pharmaceuticals: Collaborations
Table 10.28  Celyad: Collaborations
Table 11.1  Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 11.2  Cell Therapy Manufacturing: Contract Manufacturers
Table 12.1  Price of Marketed Gene / Cell Therapies
Table 12.2  Price of Marketed Targeted Drugs
Table 12.3  T-Cell Immunotherapies: Expert Opinions on Pricing
Table 12.4  CAR-T Therapies: Reimbursement Landscape
Table 13.1  CAR-T Therapies: List of Forecasted Molecules
Table 14.1  Kymriah: Drug Overview
Table 14.2  Yescarta: Drug Overview
Table 15.1  Autolus: Company Profile
Table 15.2  bluebird bio: Company Profile
Table 15.3  CARsgen Therapeutics: Company Profile
Table 15.4  Celgene: Company Profile
Table 15.5  Cell Medica: Company Profile
Table 15.6  Cellectis: Company Profile
Table 15.7  Cellular Biomedicine Group: Company Profile
Table 15.8  Innovative Cellular Therapeutics: Company Profile
Table 15.9  Kite Pharma: Company Profile
Table 15.10  Novartis: Company Profile
Table 15.11  Sinobioway Cell Therapy: Company Profile
Table 15.12  Takara Bio: Company Profile
Table 15.13  ZIOPHARM Oncology: Company Profile
Table 18.1  CAR-T Pipeline: Distribution by Type of Developer
Table 18.2  CAR-T Therapy Pipeline: Distribution by Phase of Development
Table 18.3  CAR-T Therapy Pipeline: Distribution by Target Therapeutic Area
Table 18.4  CAR-T Therapy Pipeline: Popular Target Indications
Table 18.5  CAR-T Therapy Pipeline: Distribution by Target Antigen
Table 18.6  CAR-T Therapy Pipeline: Distribution by Source of T-Cells
Table 18.7  CAR-T Therapy Pipeline: Distribution by Route of Administration
Table 18.8  CAR-T Therapy Pipeline: Active Industry Players in Clinical Development
Table 18.9  CAR-T Therapy Pipeline: Active Industry Players in Preclinical Development
Table 18.10  CAR-T Pipeline: Active Non-Industry Players in Clinical Development
Table 18.11  CAR-T Pipeline: Active Non-Industry Players in Preclinical Development
Table 18.12  CAR-Construction: Distribution by Generation of CAR-T Therapies
Table 18.13  CAR-Construction: Distribution by Type of scFv Used in CAR-T Therapies
Table 18.14  CAR-Construction: Distribution by Type of Vector
Table 18.15  CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Table 18.16  CAR-T Therapies: Popular Targets in Hematological Cancer
Table 18.17  CAR-T Therapies: Popular Targets in Solid Tumor
Table 18.18  CAR-T Clinical Trials: Cumulative Trend (Pre-2012-2018)
Table 18.19  CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
Table 18.20  CAR-T Therapies: Distribution of Clinical Trials by Phase of Development
Table 18.21  CAR-T Therapies: Distribution of Clinical Trials by Patient Segment
Table 18.22  CAR-T Therapies: Distribution of Clinical Trials by Type of Therapy
Table 18.23  Overall CAR-T Therapy Market Forecast, 2018-2030: Conservative Scenario (USD Billion)
Table 18.24  Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
Table 18.25  Overall CAR-T Therapy Market Forecast, 2018-2030: Optimistic Scenario (USD Billion)
Table 18.26  CAR-T Therapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 18.27  CAR-T Therapy Market: Distribution by Target Indication, 2025 and 2030 (USD Billion)
Table 18.28  Kymriah® (Novartis) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.29  Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.30  Kymriah® (Novartis) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.31  Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.32  Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.33  Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.34 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.35  bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.36  bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.37  MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.38  MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.39  MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.40  CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.41  CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.42  CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.43  GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.44  GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.45  GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.46  TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.47  TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.48  TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.49  JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.50  JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.51  JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.52  IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.53  IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.54  IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.55  PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.56  PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.57  PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.58  AUTO2 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.59  AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.60  AUTO2 (Autolus) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.61  AUTO3 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.62  AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.63  AUTO3 (Autolus) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.64  BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.65  BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.66  BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.67  CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.68  CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.69  CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.70  CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.71  CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.72  CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.73  LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.74  LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.75  LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.76  CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.77  CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.78  CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.79  CAR-T Therapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Companies

The following companies and organizations have been mentioned in the report: Abramson Cancer Center

  1. Abramson Cancer Center
  2. Acerta Pharma
  3. Adaptimmune Therapeutics
  4. Adicet Bio 
  5. Advent Bioservices
  6. Adverum Biotechnologies
  7. Aeon Therapeutics (Shanghai)
  8. Affiliated Hospital to Academy of Military Medical Sciences
  9. AgenTus Therapeutics
  10. AGF Private Equity
  11. Akron Biotech
  12. Allergan
  13. Amsterdam BioTherapeutics Unit 
  14. Amgen
  15. Anhui Provincial Hospital
  16. Antagene
  17. Anterogen
  18. apceth Biopharma
  19. Aquilo Capital Management
  20. ARBELE
  21. ARCH Venture Partners
  22. ARIAD Pharmaceuticals
  23. AstraZeneca
  24. Asymptote
  25. Atlantic Bio GMP
  26. Atlas Venture
  27. Aurora Biopharma
  28. Autolus
  29. Avacta
  30. AVG Ventures
  31. BankInvest Biomedical Venture
  32. Batavia Biosciences
  33. Bavarian Nordic
  34. Baxalta
  35. Bayer
  36. Baylor College of Medicine
  37. Beijing Biohealthcare Biotechnology
  38. Beijing Doing Biomedical
  39. Beijing Genomics Institute
  40. Beijing Immunochina Medical Science and Technology
  41. Beijing Sanwater Biological Technology
  42. Bellicum Pharmaceuticals
  43. BioAtla
  44. Bio Elpida
  45. Biogen
  46. BioLife Solutions
  47. bluebird bio
  48. Boehringer Ingelheim
  49. Brammer Bio
  50. Broad Institute 
  51. Bristol-Myers Squibb
  52. California Institute for Regenerative Medicine
  53. Cancer Research UK
  54. Cancer Prevention Research Institute of Texas
  55. Cartherics
  56. Caribou Biosciences
  57. Carina Biotech
  58. CARsgen Therapeutics
  59. Casdin Capital
  60. Casebia Therapeutics
  61. Cell Biotech
  62. Celdara Medical
  63. Cellectis
  64. Cell Design Labs
  65. Celgene
  66. Cell and Gene Therapy Catapult
  67. Cellenkos
  68. Cell Medica
  69. Cellular Biomedicine Group
  70. CELLforCURE
  71. Cell Therapies
  72. Cellular Therapeutics
  73. Celyad
  74. Center for Cell and Gene Therapy
  75. Changhai Hospital
  76. CHDI Foundation
  77. Chiesi Farmaceutici 
  78. Children's Hospital of Philadelphia
  79. Children's Mercy Hospital
  80. Children's Oncology Group
  81. Children's Research Institute
  82. Chinese Academy of Sciences
  83. Chinese PLA General Hospital
  84. Christie NHS Foundation Trust
  85. Clough Capital Partners 
  86. City of Hope National Medical Center
  87. Cognate BioServices
  88. Cook MyoSite
  89. Cormorant Asset Management
  90. CRISPR Therapeutics
  91. CureVac
  92. Cystic Fibrosis Foundation Therapeutics
  93. Cytovance Biologics
  94. Daiichi Sankyo
  95. Dana-Farber Cancer Institute
  96. Dartmouth College
  97. Dendreon
  98. Dongguan People's Hospital
  99. Dow AgroSciences
  100. Duke Cancer Institute
  101. EcoR1 Capital
  102. Editas Medicine
  103. Eli Lilly
  104. Endocyte
  105. ERS Genomics
  106. Eutilex
  107. Eureka Therapeutics
  108. F1 Oncology
  109. Fate Therapeutics
  110. FGP Capital
  111. Financière IDAT
  112. First Affiliated Hospital of Chengdu Medical College
  113. First Affiliated Hospital of Harbin Medical University
  114. First Affiliated Hospital of Wenzhou Medical University
  115. First Affiliated Hospital of Zhejiang University
  116. First People's Hospital of Foshan
  117. Five Prime Therapeutics
  118. Forbion Capital Partners
  119. Fondazione Telethon and Ospedale San Raffaele
  120. Foresite Capital
  121. Forevertek Biotechnology
  122. Formula Pharmaceuticals
  123. Fosun Pharmaceutical
  124. Franklin Templeton Investments
  125. Fred Hutchinson Cancer Research Center
  126. Friedreich’s Ataxia Research Alliance
  127. Fuda Cancer Hospital
  128. Fudan University
  129. Fujian Medical University
  130. Gene and Cell Therapy Lab
  131. GE Healthcare Life Sciences
  132. Gilead Sciences
  133. GlaxoSmithKline
  134. Google Ventures
  135. Green Cross Cell
  136. Guangzhou Eighth People's Hospital
  137. Guangzhou First People's Hospital
  138. Guangzhou Xiangxue Pharmaceutical
  139. Guangzhou YiYang Biological Technology
  140. Guangdong Zhaotai InVivo Biomedicine
  141. Guy's and St Thomas' NHS Foundation Trust
  142. Harbin Medical University
  143. Harvard University
  144. Hebei Senlang Biotechnology
  145. Henan Cancer Hospital
  146. H. Lee Moffitt Cancer Center and Research Institute
  147. Howard Hughes Medical Institute
  148. Human Stem Cells Institute
  149. Hunan Zhaotai Yongren Medical Innovation
  150. iCarTAB BioMed
  151. iCell Gene Therapeutics
  152. Immunocore
  153. Immune Therapeutics
  154. Immunovative Therapies
  155. Imperial College London
  156. Innovative Cellular Therapeutics
  157. Innovative Genomics Institute
  158. Intellia Therapeutics
  159. Intrexon
  160. Institut Curie
  161. Institut Pasteur
  162. Boston Children's Hospital
  163. Instituto de Salud Carlos III
  164. Iovance Biotherapeutics
  165. Iowa State University Research Foundation
  166. Janus Capital Management
  167. Janssen Biotech
  168. Jazz Pharmaceuticals
  169. JCR Pharmaceuticals
  170. Jennison Associates
  171. Jiangsu Cancer Hospital
  172. John Goldman Centre for Cellular Therapy
  173. Johns Hopkins University
  174. Jonsson Comprehensive Cancer Center
  175. Juno Therapeutics
  176. JW Biotechnology
  177. Karolinska University Hospital
  178. KBI Biopharma
  179. Khosla Ventures
  180. King's College London
  181. Kite Pharma
  182. KTB Ventures
  183. Leucid Bio
  184. Lexicon Pharmaceuticals
  185. Lonza
  186. Marino Biotechnology
  187. MaSTherCell
  188. Massachusetts General Hospital Cancer Center
  189. MaxCyte 
  190. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  191. MD Anderson Cancer Center
  192. Medarex
  193. Medical College of Wisconsin
  194. Medigene
  195. MEDINET
  196. MedImmune
  197. Memorial Sloan Kettering Cancer Center
  198. Merck
  199. Merck Serono
  200. Merlin Nexus
  201. Millennium Pharmaceuticals
  202. Miltenyi Biotec
  203. MingJu Therapeutics (Shanghai)
  204. Molecular and Cellular Therapeutics
  205. MolMed
  206. Mustang Bio
  207. Nanjing Children's Hospital
  208. Nanjing Legend Biotech
  209. NantKwest
  210. National Cancer Institute
  211. National Heart, Lung, and Blood Institute
  212. National Institutes of Health
  213. Navy General Hospital (Beijing)
  214. New Enterprise Associates
  215. New Leaf Venture Partners
  216. New River Management
  217. NewVa Capital Partners
  218. Ningbo Cancer Hospital
  219. Nikon CeLL innovation
  220. Noile-Immune Biotech
  221. Novartis
  222. ODYSSEE Venture
  223. Omega Funds
  224. OnCyte
  225. Onyx Pharmaceuticals
  226. Opexa Therapeutics
  227. Opus Bio
  228. OrbiMed HealthCare Fund Management
  229. Ospedale Pediatrico Bambino Gesù
  230. Oxford BioMedica
  231. Partners Innovation Fund
  232. Peking University
  233. Peter MacCallum Cancer Centre
  234. PersonGen BioTherapeutics (Suzhou)
  235. Pfizer
  236. PharmaCell
  237. Pharmicell
  238. Pinze Lifetechnology
  239. Polaris Partners
  240. Poseida Therapeutics
  241. Praxis Pharmaceutical
  242. Precision BioSciences
  243. Precision Genome Engineering 
  244. Princess Margaret Cancer Centre
  245. Progenitor Cell Therapy
  246. ProMab Biotechnologies
  247. Puma Biotechnology
  248. Quogue Capital
  249. Ramius Capital Group
  250. Rayne Cell Therapy Suite
  251. Redmile Group
  252. Relieve Genetics
  253. Regeneron Pharmaceuticals 
  254. Remeditex Ventures
  255. Renji Hospital
  256. Renmin Hospital of Wuhan University
  257. Ridgeback Capital Management
  258. Roche
  259. Rockland Immunochemicals
  260. Roger Williams Medical Center
  261. RoslinCT
  262. Roswell Park Comprehensive Cancer Center 
  263. Sangamo Therapeutics
  264. San Raffaele Hospital
  265. Scottish National Blood Transfusion Service
  266. Seattle Genetics
  267. Seattle Children's Hospital
  268. Second Affiliated Hospital of Guangzhou Medical University
  269. Sectoral Asset Management
  270. Second Military Medical University
  271. Servier
  272. Shanghai Bioray Laboratory
  273. Shanghai Changzheng Hospital
  274. Shanghai Chest Hospital
  275. Shanghai Children's Medical Center
  276. Shanghai GeneChem
  277. Shanghai Longyao Biotechnology
  278. Shanghai Sunway Biotech
  279. Shanghai Tongji Hospital
  280. Shanghai Unicar-Therapy Bio-medicine Technology
  281. Sheba Medical Center
  282. Shenzhen Geno-immune Medical Institute
  283. Shenzhen Institute for Innovation and Translational Medicine
  284. Shenzhen Second People's Hospital
  285. Shenzhen Sibiono GeneTech
  286. Shire International
  287. Sidney Kimmel Comprehensive Cancer Center
  288. Sigma-Aldrich
  289. Sichuan University
  290. Sinobioway Cell Therapy
  291. Sinobioway Group
  292. Spark Therapeutics
  293. Stanford University 
  294. St. Jude Children’s Research Hospital
  295. SOTIO
  296. StrideBio
  297. SR One
  298. Sun Yat-sen University
  299. Tactiva Therapeutics
  300. Takeda Pharmaceutical
  301. Takara Bio
  302. Targazyme
  303. Target ALS Foundation
  304. TC BioPharm
  305. Tesaro
  306. Terumo Medical
  307. Beijing Pregene Science and Technology Company
  308. The First Affiliated Hospital of Guangdong Pharmaceutical University
  309. The First Affiliated Hospital of Guangzhou Medical University
  310. The First Affiliated Hospital of Soochow University
  311. The First People's Hospital of Yunnan
  312. The Pregene (ShenZhen) Biotechnology Company
  313. Theravectys
  314. Henan University of Traditional Chinese Medicine
  315. Texas Emerging Technology Fund
  316. Thermo Fisher Scientific
  317. The Wistar Institute
  318. Third Military Medical University
  319. Third Rock Ventures
  320. Third Security
  321. Tianjin Medical University Cancer Institute and Hospital
  322. TiGenix
  323. TissueGene-C
  324. Tmunity Therapeutics
  325. TNK Therapeutics
  326. Tongji University School of Medicine
  327. TRACT Therapeutics
  328. Transgene
  329. Transposagen Biopharmaceuticals
  330. T. Rowe Price Associates
  331. TVAX Biomedical
  332. TVM Capital
  333. Two Blades Foundation
  334. Txcell
  335. UNC Lineberger Comprehensive Cancer Center
  336. Union Stem Cell & Gene Engineering
  337. University College London
  338. University Health Network, Toronto
  339. University of Birmingham
  340. University of British Columbia
  341. University of California
  342. University of Florida
  343. University of Milano-Bicocca
  344. University of Minnesota
  345. University of Pennsylvania
  346. University of Texas
  347. University of Zurich
  348. Uppsala University
  349. Unum Therapeutics
  350. Vaccinogen
  351. Valeant Pharmaceuticals
  352. Vecura
  353. Versant Ventures
  354. Vertex Pharmaceuticals
  355. VGXI
  356. Viking Global Investors
  357. ViroMed
  358. Vor Biopharma
  359. Washington University
  360. Weill Cornell Medical College
  361. Wellington Capital Management
  362. Wuhan Union Hospital
  363. Wuhan Sian Medical Technology
  364. WuXi AppTec
  365. Xinqiao Hospital of Chongqing 
  366. Xijing Hospital
  367. Xuzhou Medical University
  368. Zhejiang University
  369. Zhujiang Hospital
  370. ZIOPHARM Oncology
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com